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Traditional patches are most successful in transdermal delivery of low-dose hydrophobic 
drugs. Week-long transdermal delivery of high-dose hydrophilic drugs remains a big 
challenge. This study explored ablative fractional laser (AFL) to assist 3-day to week-
long sustained transdermal delivery of powder hydrophilic drugs in murine models. Bulk 
drug powder was coated into reservoir patches followed by topical application onto AFL-
treated skin. Water evaporated from AFL-generated skin microchannels (MCs) gradually 
dissolve topical drug powder to elicit multi-day sustained drug delivery. Using 
sulforhodamine b, zidovudine, and bovine serum albumin as model hydrophilic drugs, 
we found tapped coating could coat 10-20 mg drug per 0.5 cm2 reservoir patch to elicit 
3-day sustained delivery, while compression coating could coat ~35-70 mg drug per 0.5 
cm2 reservoir patch to elicit week-long sustained delivery. Besides sustained drug 
delivery, AFL-assisted powder reservoir patch delivery also showed a good safety. AFL-
generated skin MCs resealed in 1-2 days and completely recovered in 3 days after the 
week-long sustained delivery. AFL-assisted powder reservoir patch delivery involves no 
complex powder formulation and only requires incorporation of highly water-soluble 
mannitol or a similar excipient to elicit the high-efficient delivery. Enlarging reservoir 
patch size to 10 cm2 can conveniently expands the delivery capacity to gram scale. To 
our knowledge, this is the first time that high-dose week-long sustained transdermal 
delivery of hydrophilic drugs was achieved via a simple laser-based powder delivery 
platform. 
 






Transdermal delivery is highly attractive for alternative drug delivery and yet faces 
significant challenges due to the barrier function of the stratum corneum (SC) layer [1-3]. 
Only a small number of hydrophobic drugs with molecular weight ≤500 Da are able to 
penetrate the SC layer. The first transdermal patch (Scopolamine) was approved in 1979 
and since then, only two dozen transdermal products have been approved for human 
use [1, 4]. Different strategies, like chemical enhancers, iontophoresis, and ultrasound, 
were explored to disrupt SC layer to facilitate transdermal drug delivery and yet received 
limited success due to their low efficiency in SC disruption or their safety concerns [1]. 
 
Laser is a monochromatic and coherent light with broad applications in surgery and 
medicine. Laser has also been explored to ablate SC layer to facilitate transdermal drug 
delivery by taking advantage of its photothermal and photomechanical effects [5, 6]. 
Different lasers, like excimer laser, Q-switched neodymium-doped yttrium aluminum 
garnet (Nd:YAG) laser, ruby laser, erbium:yttrium scandium gallium garnet (YSGG) 
laser, and CO2 laser, have been utilized to ablate full-surface SC layer to facilitate 
transdermal drug delivery [5-9]. The degree of SC ablation was highly correlated with 
laser energy [5-9]. Low laser energy led to inefficient SC ablation, while high laser 
energy caused overt skin reactions [10]. 
 
This dilemma was effectively addressed with the advent of ablative fractional laser 
(AFL). AFL was fabricated based on ‘fractional photothermolysis’ conceptualized for 
improved skin resurfacing in cosmetic field [11]. AFL emits high-energy micro-laser 
beams to ablate tiny skin tissues and generate skin microchannels (MCs). AFL-
generated skin MCs are often tens to hundreds of micrometers in diameter and can span 
from skin surface to epidermal or dermal tissue depending on laser settings [12, 13]. 
Due to the sparing of the majority of the skin from laser ablation, AFL-treated skin can be 
quickly and completely recovered in days. Due to significantly improved safety, AFL has 
been actively explored to facilitate transdermal delivery of hydrophilic drugs. AFL was 
found to significantly enhance transdermal delivery of imiquimod, polypeptide, 
fluorescein isothiocyanate-labeled dextran, small interfering RNA, and plasmid DNA in 
mouse skin [14, 15]. AFL was also found to significantly enhance transdermal uptake of 
porphyrin precursors (methyl 5-aminolevulinate and 5’-aminolevulinic acid) and increase 
deep penetration of chemotherapy drugs (5-fluorouracil and cisplatin) in pig skin [16-19]. 
AFL was also utilized to enhance transdermal delivery of monoclonal antibodies, 
nanoparticles and microparticles [20-22]. Even living human cells could be efficiently 
delivered into AFL-treated epidermal and dermal tissues [23]. Besides preclinical 
evaluations, AFL was also explored to enhance topical delivery of corticosteroids and 
anesthetics in human subjects [24-27]. 
 
Most of the above studies focused on exploring AFL to assist short-term (≤24 hours) 
delivery of hydrophilic drugs across the skin. The potential of AFL to facilitate 3-day to 
week-long sustained delivery of hydrophilic drugs at high doses remains elusive. 
Recently, we explored AFL to facilitate 12-hour sustained transdermal delivery of 
hydrophilic drugs in a powder form [28]. Such a delivery took advantage of water 
evaporation from AFL-generated skin MCs to gradually dissolve topical drug powder 
coated in volumetric channels of thick patches to elicit ~12-hour sustained delivery [28]. 
Increasing powder coating amount may prolong the duration of drug delivery to multiple 
days. The current study coated bulk drug powder in cylindrical reservoir patches 
followed by topical application onto AFL-treated skin to elicit 3-day to week-long 
sustained drug delivery in murine models. We found tapped coating could coat 10-20 mg 
drug per 0.5 cm2 reservoir patch to elicit 3-day sustained delivery, while compression 
coating could coat ~35-70 mg drug per 0.5 cm2 reservoir patch to elicit week-long 
sustained delivery. We further found AFL-generated skin MCs could reseal in 1-2 days 
and completely recover in 3 days after the week-long sustained drug delivery, indicating 
the safety of AFL-assisted powder reservoir patch delivery.  
Materials and Methods 
Reagents 
Sulforhodamine B (SRB, 230161), zidovudine (AZT, PHR1292), bovine serum albumin 
(BSA, A2733), and mannitol (M4125) were purchased from Sigma (St. Louis, MO). 
Texas Red (TR)-conjugated BSA (TR-BSA, A23017) was purchased from Thermo 
Fisher Scientific (Waltham, MA). 
Laser device 
Lumenis Ultrapulse ablative fractional CO2 laser at different energies (2.5, 5, and 10 mJ) 
and percent coverages (5, 10, and 20%) was used in this study to generate skin MCs to 
support transdermal powder drug delivery. AFL at 5, 10, and 20% coverage was able to 
generate 11×11, 15×15, and 21×21 arrays of skin MCs in 8×8 mm2 area, respectively. 
Animals 
BALB/c mice (female, 6-8 weeks old) were purchased from Charles River Laboratories 
(Wilmington, MA). Mice were anesthetized by intraperitoneal injection of Ketamine (80 
mg/kg) and Xylazine (10 mg/kg) for hair removal, AFL treatment, and patch application. 
All animal-related procedures were approved by the Institutional Animal Care and Use 
Committee of the University of Rhode Island. 
Reservoir patch coating 
Sterile cylindrical containers with 8 mm in diameter and 5 mm in depth were used as 
reservoir patches in this study. Drugs were mixed with highly water-soluble mannitol in 
water and then lyophilized for reservoir patch coating. For tapped coating, drug/mannitol 
powder was loaded into reservoir patches with gentle tapping. For compression coating, 
blank reservoir patches were laid on flat surface of cured polydimethylsiloxane (PDMS) 
(Sylgard 184) in ultracentrifuge tubes (357007, Beckman Coulter Life Sciences) and an 
excessive amount of drug/mannitol powder was poured to cover the blank reservoir 
patches followed by centrifugation at 20,000 rpm for 90 minutes in Beckman 
Ultracentrifuge (Avanti J-E series). Powder above the surface of the reservoir patches 
was removed by a scalpel. Powder reservoir patches were kept in a desiccator before 
use. 
In vitro Franz Cell delivery 
Franz Cells with an orifice diameter of 5 mm and recipient chamber volume of 1.5 ml 
were custom-made by PermeGear (Hellertown, PA). AFL-treated skin or non-treated 
intact skin was dissected and mounted on recipient chambers. Powder reservoir patches 
were topically applied and further assembled with blank donor chambers to form Franz 
Cell systems. Phosphate-buffered saline (PBS, 1.5 ml) was added to recipient chambers 
and bubbles under the skin were carefully removed. Franz Cell systems were put on a 
temperature-controlled magnetic stirrer to maintain PBS temperature at ~34°C, similar to 
skin surface temperature of live mice [29]. A small volume of PBS (100 μl) was collected 
from the recipient chamber daily for 7 days and 100 µl fresh PBS was added back to 
maintain PBS volume the same during the entire study period. 
In vivo delivery 
Hair on the lateral back skin of BALB/c mice was removed one day before experiment by 
clipping and application of hair-removal lotion. Hair-removed lateral back skin of 8×8 
mm2 area was exposed to AFL at indicated settings to generate skin MCs. Powder 
reservoir patches were topically applied and further sealed with Tegaderm film to form 
an air-tight system. A narrow bandage was used to keep the entire system in position. 
SRB extraction and quantification 
Patch-coated SRB before delivery and patch-remaining SRB after delivery was extracted 
into PBS. SRB remaining on skin surface was harvested by washing skin surface with 
50-100 µl PBS for 3 times. SRB amounts in PBS extracts, PBS washes, and PBS 
samples in Franz Cell studies were quantified by measurement of fluorescence intensity 
at 565/586nm. Serum SRB levels were measured similarly as in our previous report [28]. 
In brief, blood (~25 µl) was collected into heparin-containing tubes and immediately 
centrifuged. Supernatants (serum) were collected and serum SRB levels were quantified 
by measurement of fluorescence intensity at 565/585nm after more than a 20-fold 
dilution in PBS. 
AZT extraction and quantification 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to quantify 
AZT levels as in our previous report [28]. In brief, patch extracts, skin surface washes, 
and AZT standards (5, 20, 50, 100, 200, 400 ng/ml) were mixed with 100 ng/ml AZT-
internal standard (AZT-IS, 3’-azido-3’-deoxythymidine, MG103, Moravek Biochemicals, 
Brea, CA). A small amount of blood (~25 µl) was collected before delivery and at 
different times after delivery to measure serum AZT levels. Serum samples were diluted 
60 times with PBS, mixed with 100 ng/ml AZT-IS, filtered through 10 kDa cutoff Amicon 
filter. The different samples were loaded into an AB Sciex 4500 QTRAP LC-MS/MS 
equipped with Shimadzu LC-20AD pumps and a QTRAP 4500 System. A Synergi 
Hydro-RP 80A, 2.0×150 mm, 4μm particle size analytical column (Phenomonex, 
Torrance, CA) was used for sample separation. Acquisition was performed in multiple 
reaction monitoring (MRM) mode using m/z 268/127 for AZT detection and 271/130 for 
AZT-IS detection. A standard curve of peak area ratios of AZT to AZT-IS against AZT 
concentrations was generated to quantify AZT levels in unknown samples.  
BSA extraction and quantification 
A small amount of blood (~25 µl) was collected daily for 6-8 days in AFL-assisted 
powder BSA delivery. Serum samples were diluted 1,000 times with PBS for 
measurement of serum BSA levels with a commercial ELISA kit (F030, Cygnus 
Technologies). For accurate quantification of BSA amount in recipient chambers in 
Franz Cell studies, 0.5 mg TR-BSA was mixed with 1.42 g BSA and TR-BSA/BSA 
mixture was then mixed with mannitol at 1:2.5 weight ratio followed by lyophilization and 
compression patch coating. Fluorescence intensity of TR-BSA in unknown samples was 
read at 596/615nm together with a 2-fold serial dilution of above prepared TR-BSA-
admixed BSA/mannitol samples. A standard curve was generated by plotting 
fluorescence intensities of TR-BSA against BSA concentrations in the 2-fold serial 
diluted samples, by which BSA amounts in unknown samples were calculated. 
Delivery efficiency 
Delivery efficiency of AFL-assisted powder reservoir patch delivery was quantified using 
the following formula: (patch coating amount - patch remaining amount - skin surface 
amount)/patch coating amount × 100%. 
Transepidermal water loss (TEWL) 
TEWL of mouse skin was measured by Tewameter TM300 (Courage-Khazaka, Köln, 
Germany) equipped with an open chamber probe with the probe head 1 cm in diameter. 
Oral gavage 
Oral gavage was performed as in our previous report [28]. In brief, a sterile plastic 
mouse-specific feeding tube (Cadence Science, Inc.) was inserted and advanced to the 
stomach when mice were restrained. AZT solutions were then administered followed by 
gentle retraction of the plastic feeding tubes. 
Histological analysis 
Skin was dissected at indicated times and fixed in formalin, embedded in paraffin, and 
sectioned at 5 µm thickness followed by hematoxylin and eosin (H & E) staining. Images 
of H & E-stained sections were taken under Nikon Eclipse E600 microscope. 
Statistical analysis 
All values were expressed as Mean ± SD (standard deviations). Student’s t-test was 
used to compare differences between groups. One-way ANOVA with Bonferroni's 
multiple comparison test was used to compare differences for more than 2 groups. P 
value was calculated by PRISM software (GraphPad, San Diego, CA) and considered 




AFL-assisted powder reservoir patch delivery of SRB 
Reservoir patches significantly increased powder coating amount. Due to the slow water 
evaporation from AFL-generated skin MCs, it remained to be explored whether the bulk 
amount of drug powder coated in reservoir patches could be fully dissolved to elicit 
efficient delivery. Using hydrophilic SRB as a fluorescence model drug, we conducted a 
pilot study and found pure SRB power coated in reservoir patches could not be 
completely dissolved by evaporated water from AFL-generated skin MCs both in vitro 
and in vivo (data not shown). Based on our previous experience [28], highly water-
soluble mannitol was mixed with SRB at 1:1 weight ratio with a promise to increase 
powder SRB delivery. We found ~40 mg SRB/mannitol powder containing ~20 mg SRB 
could be coated per reservoir patch with 0.5 cm2 surface area. AFL-assisted powder 
reservoir patch delivery of SRB in the presence of mannitol was first explored in Franz 
Cell systems. Skin of BALB/c mice was treated with AFL at low (2.5 mJ/5%), medium (5 
mJ/10%), or high laser setting (10 mJ/20%). AFL-treated skin or non-treated intact skin 
was dissected and mounted on recipient chambers of Franz Cell systems followed by 
topical application of powder SRB/mannitol (1:1)-coated reservoir patches (hereafter 
powder SRB-coated reservoir patches), as shown in Fig.1A. SRB levels in recipient 
chambers were measured daily for 7 days. 
 
No significant SRB delivery was observed on day 1 (Fig.1B). SRB levels quickly 
increased from day 1 to 3 in high laser group and then slowly increased afterwards 
(Fig.1B). SRB levels quickly increased from day 1 to 4 in medium laser group and then 
slowly increased afterwards (Fig.1B). SRB levels remained at low levels in the first 2 
days in low laser group, slowly increased from day 2 to 3, quickly increased from day 3 
to 6, and plateaued on day 7 (Fig.1B). The above data indicated a positive correlation 
between laser intensities and SRB delivery rates. SRB levels reached 13.3, 11.9, and 
12.7 mg/mL on day 7 in high, medium, and low laser groups, respectively (Fig.1B). 
Considering ~20 mg SRB was coated per reservoir patch and 1.5 mL PBS was added to 
recipient chambers, the overall SRB delivery efficiency was estimated to be at least 90% 
for all laser conditions. In comparison, SRB levels remained below 0.8 mg/mL in intact 
skin group (Fig.1B), indicating no significant SRB delivery across intact skin. At the end 
of delivery, no SRB powder could be found in laser groups, while the majority of SRB 
powder remained in intact skin group. The lag time of one day in medium and high laser 
groups and 2 days in low laser group is unique to AFL-assisted powder reservoir patch 
delivery considering the bulk amount of drug powder needs to be first dissolved to elicit 
efficient delivery across AFL-treated skin. The Franz Cell study indicated AFL-assisted 
powder reservoir patch delivery could elicit week-long sustained SRB delivery in vitro. 
 
Fig. 1. AFL-assisted week-long sustained SRB delivery in vitro 
A. Illustration of Franz Cell systems to explore AFL-assisted powder reservoir patch 
delivery. AFL-treated or intact skin was mounted on recipient chambers followed by 
topical application of powder drug-coated reservoir patches. Donor chambers were then 
put on top to complete Franz Cell assembly. Recipient chambers were filled with 1.5 mL 
PBS and donor chambers were left blank. B. Lateral back skin of BALB/c mice was 
exposed to AFL at low, medium, or high laser setting, or left non-treated. Skin was 
dissected and mounted on recipient chambers of Franz Cell systems followed by topical 
application of powder SRB-coated reservoir patches. Cumulative SRB delivery in 
recipient chambers was explored daily for 7 days. n=6 
 
Next, we explored AFL-assisted powder reservoir patch delivery of SRB in vivo. Lateral 
back skin of BALB/c mice was treated with low, medium, or high laser, or left non-treated 
followed by topical application of powder SRB-coated reservoir patches. Patches were 
removed daily for 3 days to measure the delivery efficiency. As shown in Fig.2A, ~67%, 
51%, and 25% SRB was delivery at 24 hours in high, medium, and low laser groups, 
respectively. Delivery efficiency increased to ~92%, 75%, and 54% at 48 hours in high, 
medium, and low laser groups, respectively (Fig.2A). Delivery efficiency reached more 
than 95% in high and medium laser groups and more than 85% in low laser group at 72 
hours (Fig.2A). In comparison, less than 1% SRB was delivered in intact skin group and 
the majority of SRB remained as a powder form at each time point (Fig.2A). The above 
study indicated AFL could assist 3-day sustained powder SRB delivery in live mice. 
Systemic SRB delivery was further explored in AFL-assisted 3-day sustained powder 
delivery. As shown in Fig.2B, serum SRB quickly increased and peaked at ~32 µg/mL at 
12 hours in high laser group and then gradually reduced to below 3 µg/mL at 72 hours 
(Fig.2B). Serum SRB remained at relatively low levels in the first 8 hours in medium 
laser group, quickly increased to peak levels (8-10 µg/mL) between 12-24 hours, and 
gradually reduced to below 4 µg/mL at 72 hours (Fig.2B). Serum SRB levels remained 
below 2 µg/mL in low laser and intact skin groups in entire delivery period (Fig.2B). Area-
under-the Curve (AUC) was calculated to be 810, 361, and 61 μg·hr/ml in high, medium, 
and low laser groups, respectively. Lack of significant increase of serum SRB in low 
laser group is expected to be a net result of slow SRB delivery (Fig.1B) and quick SRB 
clearance. According to one report [30], half SRB could be cleared from peripheral blood 
in minutes. The above results indicated the positive correlation between serum SRB 
levels and laser intensities in AFL-assisted powder reservoir patch delivery. The above 
results also indicated more rapid SRB delivery in live mice than in Franz Cell systems. 
We also explored local safety and MC resealing kinetics in AFL-assisted powder SRB 
delivery at low laser condition. Skin MCs were clearly visible right after AFL treatment 
(left, Fig.2C) and invisible at the end of 3-day delivery (right, Fig.2C). No significant skin 
reactions were found except clear signs of the boundaries of reservoir patch application 
(right, Fig.2C). Kinetics of skin MC resealing were studied by measurement of TEWL of 
AFL-treated skin at different time points. As shown in Fig.2D, AFL treatment (2.5 mJ/5%) 
instantly increased TEWL of the skin from baseline (~6 g/hm2) to ~85 g/hm2. TEWL of 
AFL-treated skin reduced to ~40 g/hm2 measured shortly after patch removal 3 days 
later, hinting partial resealing of skin MCs. TEWL of AFL-treated skin returned to 
baseline levels 36 hours after patch removal, hinting complete resealing of skin MCs 
(Fig.2D). Quick resealing of skin MCs was expected to reduce infection risks of 
environmental pathogens. To explore impacts of reservoir patch application on skin MC 
resealing, we measured TEWL of AFL-treated skin at different time points in the 
absence of reservoir patch application. We found TEWL of AFL-treated skin returned to 
baseline levels in 1-2 days (Fig.2E). The above results indicated reservoir patch 
application could delay skin MC resealing. We further found blank patch application 
could also delay skin MC resealing but was less effective than powder patch application 
(data not shown). 
 
Fig. 2. AFL-assisted 3-day sustained SRB delivery in vivo 
A. Powder SRB-coated reservoir patches were topically applied onto AFL-treated or 
intact skin of BALB/c mice. Patches were removed daily for 3 days to evaluate the 
delivery efficiency. n=4-5. B. Powder SRB-coated reservoir patches were topically 
applied onto AFL-treated skin or intact skin of BALB/c mice followed by patch removal 3 
days later. A small amount of blood was collected at different time points (3, 6, 9, 12, 16, 
20, 26, 32, 36, 42, 48, 54, 60 and 72 hours) to quantify serum SRB levels. C. Lateral 
back skin of BALB/c mice was exposed to AFL (2.5 mJ/5%) followed by topical 
application of powder SRB-coated reservoir patches. Patches were removed 3 days 
later. Skin pictures were taken right after AFL treatment (left) and patch removal (right). 
Arrows in the left panel pointed to AFL-generated skin MCs. Arrows in the right panel 
pointed to the boundaries of reservoir patch application. Scale: 667 µm. D. Lateral back 
skin of BALB/c mice was exposed to AFL (2.5 mJ/5%) followed by topical application of 
powder SRB-coated reservoir patches as in C. Patches were removed 3 days later. 
TEWL was measured before and right after AFL treatment, right after and at different 
time points after patch removal. E. Lateral back skin of BALB/c mice was exposed to 
AFL (2.5 mJ/5%). TEWL was measured before AFL treatment or at different time points 
after AFL treatment. n=4-5. One-way ANOVA with Bonferroni's multiple comparison test 
was used to compare differences between groups in D and E. **, p<0.01; ***, p<0.001. 
NS: not significant. 
Dynamics of powder dissolution 
Dynamics of powder dissolution were then explored after topical application of powder 
SRB-coated reservoir patches onto AFL (2.5 mJ/5%)-treated skin of BALB/c mice. SRB 
is a black powder and turns into a strong pink color after wetting or dissolution. Here, a 
trace amount of SRB was mixed with bulk amount of mannitol for sensitive detection of 
powder dissolution and delivery. As shown in Fig.3, SRB/mannitol powder mainly 
showed white mannitol color at the beginning of the delivery due to the dominant 
mannitol content. SRB/mannitol powder turned into light pink at 4 hours, indicating 
absorption of evaporated water (Fig.3). Entire powder turned into pink-colored wet mass 
at 12 hours due to continuous absorption of evaporated water and increased water 
content (Fig.3). Wet mass gradually shrank and turned into a pink-colored liquid at 60 
hours and a clear liquid with little or no pink color at 72 hours (Fig.3). This study clearly 
indicated the gradual physical change of powder during the 3-day in vivo delivery from 
the initial dry powder, to powder with increased water content, to a wet mass, and lastly 
to a liquid form. This study also indicated significant drug delivery occurred when drug 
powder was converted to a wet mass before transition to a liquid form. 
 
Fig.3 Dynamics of powder dissolution and delivery in AFL-assisted powder 
reservoir patch delivery in vivo  
Powder SRB/mannitol (1:50,000)-coated reservoir patches were topically applied onto 
AFL (2.5 mJ/5%)-treated skin of BALB/c mice. Patch images were taken at indicated 
times and representative patch images were shown. 
 
AFL-assisted 3-day sustained AZT delivery 
Using model drug SRB, we found AFL could assist 3-day sustained SRB delivery. Next, 
we explored whether the same delivery platform could be used for 3-day sustained AZT 
delivery. AZT is a nucleoside reverse transcriptase inhibitor and was the first 
antiretroviral drug approved to treat human immunodeficiency virus (HIV) [31]. Although 
more than 2 dozen antiretroviral drugs have been approved to treat HIV ever since, poor 
medication adherence was identified as a major barrier in antiretroviral therapy [32]. 
Sustained delivery technologies are highly demanded to reduce dosing frequency and 
improve the efficacy of antiretroviral therapy. To explore whether AFL could assist 3-day 
sustained AZT delivery, AZT was mixed with mannitol at 1:1 and also 1:2.5 and 1:5 
weight ratios to prepare lyophilized powder for reservoir patch coating considering AZT 
had less water solubility than SRB (20 vs. 100 mg/ml). We found 20.3, 11.4, and 6.6 mg 
AZT could be coated per reservoir patch at 1:1, 1:2.5, and 1:5 mixing ratios, respectively 
(Table 1). Patches were topically applied onto AFL (2.5 mJ/5%)-treated skin of BALB/c 
mice and removed 3 days later. We found 51% AZT at 1:1 mixing ratio and more than 
90% AZT at 1:2.5 and 1:5 mixing ratios were delivered in 3 days (Table 1). These results 
indicated AZT needed to be mixed with at least 2.5 times more mannitol to elicit efficient 
delivery across AFL (2.5 mJ/5%)-treated skin. 
Table 1. Pharmacokinetics of AFL-assisted powder AZT delivery under tapped coating 













AFL (1:1) 20.3±0.7 51±12 10.0±2.2 20 265 49% 
AFL (1:2.5) 11.4±0.4 93±3 9.8±2.6 26 249 80% 
AFL (1:5) 6.6±0.2 90±10 6.8±3.9 26 131 72% 
Oral 0.32 100 7.0±0.8 0.5 8.7 100% 
* Relative bioavailability=𝐴𝐴𝐴𝐴𝐴𝐴 (𝐴𝐴𝐴𝐴𝐴𝐴)
𝐴𝐴𝐴𝐴𝐴𝐴 (𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜)




Serum AZT levels were also measured in above studies. As shown in Fig.4A-C, dual-
phase delivery was observed with the first-phase delivery started right after patch 
application and the second-phase delivery started 12 hours after patch application. At 
1:1 mixing ratio with 51% delivery efficiency, big variations of serum AZT levels were 
observed in the second-phase delivery (Fig.4A). At 1:2.5 and 1:5 mixing ratios with more 
than 90% delivery efficiency, less variability of serum AZT levels was observed in the 
second-phase delivery (Fig.4B & C). By comparing AUC of the first-phase and second-
phase deliveries at 1:2.5 and 1:5 mixing ratios, we found less than 2% AZT was 
delivered in the first phase and more than 98% AZT was delivered in the second phase. 
Serum AZT levels peaked between 20-26 hours and then gradually reduced to baseline 
levels at 72 hours (Fig.4B & C). Powder AZT-coated reservoir patches were also 
topically applied on intact skin surface and the majority of AZT powder remained at the 
end of the 3-day delivery, indicating no significant SRB delivery in the absence of AFL 
treatment (data not shown). We also conducted oral AZT delivery to compare with the 
above AFL-assisted powder reservoir patch delivery. As shown in Fig.4D, oral delivery 
only lasted for 6 hours and serum AZT levels peaked at 0.5 hour. AUC was then 
compared among the different deliveries. As shown in Table 1, AUC of AFL-assisted 
powder AZT delivery at 1:1, 1:2.5, and 1:5 mixing ratios was ~265, 249 and 131 
μg·hr/ml, respectively, and AUC of oral AZT delivery was ~8.7 μg·hr/ml. Relative 
bioavailability of AFL-assisted powder AZT delivery at 1:1, 1:2.5, and 1:5 mixing ratios to 
oral delivery was 49, 80, and 72%, respectively (Table 1). These data indicated a 
maximum of 11.4 mg AZT could be coated per reservoir patch to elicit 3-day sustained 
delivery across AFL-treated skin. 
 
Fig. 4 AFL-assisted 3-day sustained AZT delivery in vivo  
A-C. Lateral back skin of BALB/c mice was exposed to AFL (2.5 mJ5/%) followed by 
topical application of powder AZT-coated reservoir patches at 1:1 (A), 1:2.5 (B), or 1:5 
mixing ratio (C). A small amount of blood (~25 µl) was collected before delivery and 1, 3, 
6, 9, 12, 16, 20, 26, 32, 36, 42, 48, 54, 60, and 72 hours after delivery to measure serum 
AZT levels. D. BALB/c mice were subjected to oral delivery of 0.32 mg AZT. A small 
amount of blood (~25 µl) was collected before delivery and 0.5, 1, 1.5, 2, 2.5, 3 and 6 
hours after delivery to measure serum AZT levels. n=6 
AFL-assisted week-long sustained AZT delivery 
After achieving 3-day sustained AZT delivery, we explored whether AFL could support 
week-long sustained AZT delivery. To this end, centrifugal forces were applied to 
increase powder coating amount with a promise to extend drug release beyond 3 days. 
AZT was mixed with mannitol at 1:2.5 weight ratio for powder preparation and 
compression coating. We found ~67.5 mg AZT could be coated per reservoir patch 
under compression coating, corresponding to a 6-fold increase of coating amount as 
compared to tapped coating. Lateral back skin of mice was exposed to AFL (10 mJ/5%) 
followed by topical application of compression-coated AZT patches. Here, 10 mJ laser 
energy was used to generate bigger skin MCs that were more promising to elicit efficient 
delivery under compression coating than the previously explored 2.5 mJ energy. As 
shown in Fig.5A, dual-phase 6-day sustained AZT delivery was observed. The first-
phase delivery started right after patch application and lasted for 16 hours (Fig.5A). The 
second-phase delivery started 16 hours after patch application and lasted for ~5 days 
(Fig.5A). Around 2.5% AZT was delivered in the first phase and more than 97% AZT 
was delivered in the second phase (Fig.5A). As compared to tapped coating, 
compression coating slightly extended the first-phase delivery and more significantly 
extended the second-phase delivery. Serum AZT levels peaked 20 hours after delivery 
and were maintained at peak levels till 60 hours after delivery (Fig.5A). Serum AZT 
levels gradually reduced to baseline levels afterwards (Fig.5A). At the end of delivery, 
only a small volume of liquid was found in reservoir patches and the overall delivery 
efficiency reached more than 94%. This study support compression coating to increase 
powder coating amount and extend drug release to 6 days. In comparison, no significant 
delivery was observed when compression-coated powder AZT patches were topically 
applied on intact skin (data not shown). 
 
Fig.5 AFL-assisted 6-day sustained AZT delivery in vivo 
A. Lateral back skin of mice was exposed to AFL (10 mJ/5%) followed by topical 
application of compression-coated powder AZT patches. Patches were removed 6 days 
later. A small amount of blood (~25 µl) was collected before delivery and 1, 3, 6, 12, 16, 
20, 26, 32, 40, 44, 48, 54, 60, 72, 96, 120, and 144 hours after delivery to measure 
serum AZT levels. B. BALB/c mice were subjected to AFL-assisted powder AZT delivery 
as in A. Patches were removed 7 days later. TEWL was measured before and right after 
AFL treatment, and right after and 24 hours after patch removal. C. BALB/c mice were 
subjected to AFL-assisted powder AZT delivery as in B. Skin was dissected at indicated 
time points followed by standard histological analysis. Representative images of H & E-
stained skin sections were shown. Arrows pointed to AFL-generated skin MCs. Scale: 
200 µm. n=4-5. One-way ANOVA with Bonferroni's multiple comparison test was used to 
compare differences between groups in B. ***, p<0.001. NS: not significant. 
We further explored whether AFL-generated skin MCs could remain open for 7 days to 
support week-long sustained delivery. Lateral back skin of mice was exposed to AFL (10 
mJ/5%) followed by topical application of powder AZT-coated reservoir patches as in 
above studies. Patches were removed 7 days later and TEWL was monitored before and 
after AFL treatment, and right after and 24 hours after patch removal. As shown in 
Fig.5B, TEWL of the skin increased to ~130 g/hm2 right after AFL treatment and reduced 
to ~25 g/hm2 after patch removal 7 days later. TEWL of the skin returned to near 
baseline level 24 hours after patch removal (Fig.5B). Histological analysis was further 
conducted to explore skin MC resealing and microscopic skin recovery after the week-
long sustained AZT delivery. Right after AFL (10 mJ/5%) treatment, skin MCs with ~100 
µm in diameter were visible (Fig.5C). After week-long sustained AZT delivery, skin MCs 
partially resealed and re-epithelialization occurred around skin MCs (Fig.5C). Re-
epithelialization almost completed 24 hours after patch removal and skin completely 
recovered 72 hours after patch removal (Fig.5C). These data indicated AFL-treated skin 
could be completely recovered in 3 days after AFL-assisted week-long sustained powder 
AZT delivery. 
  
AFL-assisted week-long sustained BSA delivery 
Besides small chemicals, we also explored whether macromolecules could be 
sustainably delivered via AFL-assisted powder reservoir patch delivery. BSA (~66 kDa) 
was used as a model drug to explore this first in Franz Cell systems. BSA was mixed 
with mannitol at 1:2.5 weight ratio and then lyophilized for compression coating. A trace 
amount of TR-BSA was added to BSA/mannitol mixture for accurate quantification of 
BSA amount without interference of proteins that might release from dissected skin 
during the 7-day incubation period. AFL (10 mJ/10%)-treated or intact skin was mounted 
on recipient chambers followed by topical application of powder BSA-coated reservoir 
patches that contained ~38 mg BSA per patch. Considering slow powder dissolution 
contributes to AFL-assisted multi-day sustained powder drug delivery, topical application 
of liquid drugs is expected to elicit more rapid delivery. To this end, the same amount of 
BSA/mannitol powder as coated per reservoir patch was dissolved in 1 mL PBS and 
then added to donor chambers to explore liquid BSA delivery across AFL (10 mJ/10%)-
treated skin in Franz Cell systems. Cumulative BSA delivery in recipient chambers was 
monitored daily for 7 days. As shown in Fig.6A, BSA levels slowly increased in the first 2 
days of AFL-assisted powder BSA delivery, quickly increased from day 2 to 4, and then 
slowly increased from day 4 to 7. In AFL-assisted liquid BSA delivery, BSA levels quickly 
increased in the first 2 days and then slowly increased from day 2 to 7 (Fig.6A). BSA 
levels reached 22.1 mg/mL at the end of AFL-assisted powder BSA delivery and 8.5 
mg/mL at the end of AFL-assisted liquid BSA delivery (Fig.6A). Due to 1.5 mL PBS 
added to recipient chambers, the delivery efficiency was estimated to be more than 85% 
in AFL-assisted powder BSA delivery and ~34% in AFL-assisted liquid BSA delivery. 
Higher efficiency of AFL-assisted powder BSA delivery might be due to the steep 
concentration gradient established between reservoir patches and the skin when the 
majority of BSA powder was converted to a wet mass. In comparison, the same amount 
of BSA was dissolved in 1 mL PBS and added to donor chambers in AFL-assisted liquid 
BSA delivery, which was expected to generate less steep concentration gradient 
between donor chambers and the skin considering reservoir patches had a volume of 
only 0.25 mL and powder remained as a wet mass without complete dissolution during 
an extended period in AFL-assisted powder BSA delivery. As expected, no significant 
BSA delivery was observed in intact skin group (Fig.6A). 
 
Fig.6 AFL-assisted week-long sustained BSA delivery 
A. AFL (10 mJ/10%)-treated or intact skin of BALB/c mice was mounted on recipient 
chambers of Franz Cell systems followed by topical application of compression-coated 
powder BSA patches. For liquid BSA delivery, the same amount of BSA/mannitol 
powder as coated per reservoir patch was dissolved in 1 mL PBS and then added to 
donor chambers of Franz Cell systems. Cumulative SRB delivery in recipient chambers 
was monitored daily for 7 days. B. Lateral back skin of BALB/c mice was exposed to 
AFL at 10 mJ energy and different coverages (5, 10, and 20%) or left non-treated 
followed by topical application of compression-coated powder BSA patches. Serum BSA 
levels were quantified daily for 6 days in 10 and 20% laser groups and 8 days in 5% 
laser and intact skin groups. n=4-6. 
 
Next, we explored AFL-assisted powder BSA delivery in vivo. AFL at 10 mJ energy and 
different percent coverages (5, 10, and 20%) was used to generate skin MCs to explore 
whether powder BSA delivery was affected by laser percent coverage. Compression-
coated powder BSA patches were topically applied onto AFL-treated skin or intact skin 
surface. Serum BSA levels were quantified daily for 6-8 days. Serum BSA levels quickly 
increased and peaked at 146 µg/mL on day 2 in 20% laser group, and then slowly 
reduced to 16.6 µg/mL on day 6 (Fig.6B). Serum BSA levels quickly increased and 
peaked between 50-60 µg/mL in 2 days in 10% laser group, and then gradually reduced 
to 10.4 µg/mL on day 6 (Fig.6B). Serum BSA levels in 5% laser group were relatively low 
(≤10 µg/mL) in the entire delivery period (Fig.6B). Here, we also compared the relative 
rate of AFL-assisted powder BSA delivery in vivo and in vitro at the same laser condition 
(10 mJ/10%). We found the most rapid BSA delivery occurred in 2 days in vivo and 
between day 2-4 in vitro. This indicated more rapid AFL-assisted in vivo versus in vitro 
BSA delivery, as observed in SRB studies (Fig.1 & 2). Powder-liquid transition occurred 
between day 2-3 in 10 and 20% laser groups and between day 5-6 in 5% laser group. 
Delivery efficiency reached more than 85% in all laser groups at the end of the delivery. 
In comparison, no significant BSA delivery was observed in intact skin group and the 
majority of BSA remained as a powder form at the end of the delivery. When comparing 
serum BSA levels at the late stage of delivery, we found serum BSA levels in all laser 
groups were significantly higher than that in intact skin group on day 6 and serum BSA 
levels in 5% laser group were significantly higher than that in intact skin group on day 7 
and 8 (Table 2). These data indicated AFL-assisted powder reservoir patch delivery 
could support at least week-long sustained BSA delivery in murine models. Interestingly, 
despite nearly complete BSA delivery in all laser groups, AUC showed a positive 
correlation to laser percent coverage: 41 µg∙day/mL in 5% laser group, 153 µg∙day/mL in 
10% laser group, and 378 µg∙day/mL in 20% laser group. 
 
Table 2. Comparison of serum BSA levels at late stage of week-long delivery 
 AFL/20% AFL/10% AFL/5% Intact 
skin 
p value (vs. Intact skin) 
AFL/20%  AFL/10% AFL/5% 
Day 6 16.6±10.7 10.4±5.7 10.0±8.6 1.7±0.6 0.008 (**) 0.006 (**) 0.040 (*) 
Day 7 - - 7.4±6.0 1.7±0.7 - - 0.042 (*) 
Day 8 - - 4.8±2.6 1.8±0.5 - - 0.022 (*) 
Note: *, p<0.05; **, p<0.01.  
Discussion 
This study explored AFL to assist 3-day to week-long sustained transdermal delivery of 
hydrophilic drugs in murine models. Such a delivery was based on AFL treatment to 
generate skin MCs followed by topical application of powder drug-coated reservoir 
patches to deliver drugs into the skin via skin MCs. Water evaporation from AFL-
generated skin MCs played a crucial role in converting the bulk drug powder into a wet 
mass to elicit the multi-day sustained delivery. AFL-assisted powder reservoir patch 
delivery could efficiently deliver both small chemical drugs and macromolecules. This 
study found tapped coating could coat ~11 mg AZT and 20 mg SRB per reservoir patch 
to elicit 3-day sustained delivery (Fig.2 & 4), while compression coating could coat ~38 
mg BSA and 68 mg AZT per reservoir patch to elicit 6-8-day sustained delivery (Fig.5 & 
6). Considering reservoir patches used in our studies have a surface area of 0.5 cm2, 
compression coating achieved a coating capacity of 76 mg/m2 for BSA and 136 mg/m2 
for AZT. High-dose transdermal delivery of hydrophilic drugs were also explored in two 
previous studies [33, 34]. In one study, ibuprofen sodium formulated with 
poly(methylvinyl ether/maleic acid) (PMVE/MA) polymer was loaded into the 
microneedle (MN) baseplate with an estimated coating capacity of ~74 mg/cm2 [33]. In 
the other study, lyophilized wafers were combined with hydrogel-forming MNs to deliver 
high-dose small chemical and macromolecular drugs across the skin with an estimated 
coating capacity of 53 mg/cm2 for ibuprofen sodium and 1.1 mg/cm2 for ovalbumin [34]. 
We achieved ~2 times higher coating and delivery capacity for small chemical drugs and 
~70 times higher coating and delivery capacity for macromolecules in this study. Delivery 
capacity of AFL-assisted powder reservoir patch delivery can be further expanded by 
enlarging patch size. A reservoir patch size of 10 cm2, similar to traditional 
buprenorphine patch BuTrans® and estradiol patch Climara®, is expected to have a 
coating capacity of 220-400 mg with tapped coating and 760-1,360 mg with compression 
coating. The reservoir patches used in our studies have a depth of 5 mm, which are 
expected to have a good wearability in humans considering typical watches have a 
thickness of 7 or 9 mm. Increasing reservoir patch depth to 7 or 9 mm is expected to 
increase the delivery capacity to over 1 g under compression coating. The high-dose 
AFL-assisted powder reservoir patch delivery is expected to significantly increase the 
number of hydrophilic drugs that can be delivered via transdermal route. 
 
AFL-assisted high-dose powder drug delivery is attributed to the following factors. 
Powder drugs can be directly coated and only one excipient (mannitol) is required to mix 
with hydrophilic drugs to elicit high-efficient delivery. Compression coating also 
significantly increases powder coating amount and extends drug release. In AFL-
assisted powder AZT delivery, we found compression coating slightly extended the first-
phase delivery and more significantly extended the second-phase delivery (Fig.5A). The 
reason of compression coating to extend drug release remains to be explored but may 
be related to longer time for evaporated water to convert compression-coated drug 
powder to a wet mass and longer time for more drugs under compression coating to 
diffuse into the skin via skin MCs. This study found highly water-soluble mannitol could 
facilitate AFL-assisted powder reservoir patch delivery. Mannitol most likely works to 
facilitate water absorption and transition of bulk drug powder to a wet mass. As indicated 
by the imaging study (Fig.3), significant drug delivery occurred when the bulk drug 
powder was converted to a wet mass. Mannitol is able to absorb large amounts of water 
and deliquesce after the flow moisture point was reached [35]. Thus, condensed water 
during the process of deliquescence is likely to facilitate dissolution of less water-soluble 
drugs to facilitate their transdermal delivery via skin MCs. 
 
Dual-phase SRB and AZT delivery was observed following AFL-assisted powder 
reservoir patch delivery in vivo. The first-phase delivery started right after patch 
application and the second-phase delivery started 8-16 hours after patch application. 
The first-phase delivery was likely contributed by powder in close proximity to skin MCs, 
while the second-phase delivery was likely contributed by the remaining powder after 
conversion to a wet mass. AFL-assisted powder reservoir patch deliery of BSA also 
showed dual-phase delivery as indicated by the Franz Cell studies: slow BSA delivery in 
the first 2 days and fast BSA delivery between day 2 to 4 (Fig.6A). The lack of dual-
phase delivery of BSA in vivo was most likely due to no blood collection in the first 24 
hours to analyze serum BSA levels. AUC of AFL-assisted powder SRB and BSA delivery 
was positively correlated with laser intensity (Fig.2B & Fig.6B), which seemed 
contradictive to the high delivery efficiency in all laser conditions. Such a contradiction 
can be explained by the net result of drug delivery and systemic clearance (for SRB) or 
local uptake (for BSA). Fast delivery in strong laser conditions overcame drug clearance 
or local uptake effect, resulting in an increase of serum drug levels. In contrast, slow 
delivery in weak laser condition failed to overcome drug clearance or local uptake effect, 
leading to minimal increase of serum drug levels. Our studies found Franz Cell systems 
could be used to predict the relative rate of AFL-assisted powder drug delivery in vivo 
under different laser conditions. Yet, the overall rate of drug delivery was found to be 
slower in Franz Cell systems than in vivo studies. This might be caused by slower rate of 
water evaporation in vitro than in vivo. Due to the lack of blood flow in dissected skin, 
dermal interstitial water couldn’t be replenished as in vivo studies. Although water in 
recipient chambers might replenish the lost water in dissected skin, such a process was 
expected to be less efficient than in vivo systems. 
 
AFL-assisted week-long sustained powder drug delivery was found to have a good 
safety. Skin MCs resealed in 2 days and completely recovered in 3 days at the end of 
the week-long AZT delivery (Fig.5B-C). One major safety concern of AFL-assisted 
powder drug delivery is the potential pathogen infection via open skin MCs. Disinfection 
of skin surface before delivery, patch occlusion during delivery, and quick resealing of 
skin MCs at the end of delivery are expected to significantly reduce local infection risks. 
AFL-assisted powder drug delivery takes advantage of water evaporation from skin MCs 
to dissolve topical drug powder. Although reservoir patches used in our study had a 
volume of 0.25 mL, water evaporated into reservoir patches was expected to be much 
less than 0.25 mL due to the occupation of the majority of patch volume by drug powder. 
At the end of most of the in vivo deliveries, only a small volume of liquid could be 
recovered (<50 µl), indicating minimal water loss and little impact on animal health in 
AFL-assisted powder reservoir patch delivery. For potential clinical translation, a 
proportionally increased water loss (<1 mL) with 10 cm2 patch size is not expected to 
pose a significant risk to human health. 
 
MNs have been also explored to generate skin MCs to support week-long sustained 
drug delivery. Due to the quick resealing of MN-generated skin MCs in 2 hours without 
occusion and in 2 days with occlusion [36], HMG-CoA reductase inhibitor Fluvastatin 
and non-specific COX inhibitor Diclofenac were used to delay skin MC resealing to 
support week-long sustained drug delivery [37, 38]. We found AFL (10 mJ/5%)-
generated skin MCs could remain open for 7 days with reservoir patch occlusion to 
support week-long sustained drug delivery (Fig.5). The ability of AFL to generate skin 
MCs to support week-long sustained drug delivery without application of micropore 
lifetime extenders is expected to be due to the relatively big MCs generated by AFL. AFL 
ablates tiny skin tissues to generate skin MCs, while MN insertion forces skin tissues to 
separate to generate skin MCs and MN retraction causes partial MC closure [39]. As of 
such, relatively small MCs were formed even with the use of relatively big MNs [39]. 
From this regard, laser may be a more promising technology to generate skin MCs to 
support week-long sustained drug delivery. 
 
This study found AFL could facilitate week-long sustained AZT and BSA delivery. Week-
long sustained delivery is promising to reduce dosing frequency and improve medication 
adherence in antiretriviral therapy or treatment of growth hormone deficiencies if a small 
handheld AFL device can be fabricated to support powder reservoir patch delivery. 
Furthermore, an integrated laser ablation and patch application system that combines 
the two-step delivery into one and a flexible reservoir patch that responds to delivery 
volume changes would greatly facilitate clinical translation of AFL-assisted week-long 
powder drug delivery. Drugs are mostly maintained in a wet and warm environment 
(~34°C) on skin surface in AFL-assisted week-long sustained powder drug delivery. 
Most of the chemical drugs are expected to have a good stability in AFL-assisted week-
long powder delivery. For protein-based drugs that are sensitive to increased 
temperatures, trehalose known to stabilize proteins in various harsh environments may 
be used to maintain protein activity during the week-long sustained drug delivery [40]. 
Also guinea pigs or miniature pigs with similar skin to human skin are required to 
validate AFL-assisted week-long sustained powder drug delivery. Laser parameters and 
drug/mannitol mixing ratios can be modified to obtain similar delivery kinetics in guinea 
pigs or miniature pigs.  
 
Conclusion 
This study explored AFL to assist 3-day to week-long sustained delivery of high-dose 
hydrophilic drugs in murine models. Our data indicate bulk drug powder can be coated in 
reservoir patches followed by topical application onto AFL-treated skin to elicit multi-day 
sustained delivery with a good efficiency and safety. About 10-20 mg drug can be coated 
per 0.5 cm2 reservoir patch to elicit 3-day sustained delivery with tapped coating. About 
35-70 mg drug could be coated per 0.5 cm2 reservoir patch to elicit week-long sustained 
delivery with compression coating. Enlarging reservoir patch size to 10 cm2 is expected 
to increase the maximal coating and delivery capacity to gram scale to meet the delivery 
needs of many hydrophilic drugs in clinics. Week-long sustained transdermal drug 
delivery is promising to reduce dosing frequency and improve medication adherence in 
treatment of long-term chronic diseases, such as HIV, hypertension, and diabetes. AFL-
assisted powder reservoir patch delivery involves no complex powder formulation and 
only highly water-soluble mannitol (or a similar excipient) is required to facilitate the high-
efficient delivery. To our knowledge, this is the first time that week-long sustained 
transdermal delivery of high-dose hydrophilic chemical and macromolecular drugs was 
achieved with a simple laser-based delivery platform. 
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